HomeCompareJAMF vs PFE

JAMF vs PFE: Dividend Comparison 2026

JAMF yields 15.33% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $27.1K in total portfolio value· pulled ahead in Year 9
10 years
JAMF
JAMF
● Live price
15.33%
Share price
$13.05
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.4K
Annual income
$1.71
Full JAMF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — JAMF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJAMFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JAMF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JAMF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JAMF
Annual income on $10K today (after 15% tax)
$1,302.68/yr
After 10yr DRIP, annual income (after tax)
$1.45/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,318.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JAMF + PFE for your $10,000?

JAMF: 50%PFE: 50%
100% PFE50/50100% JAMF
Portfolio after 10yr
$36.0K
Annual income
$13,130.21/yr
Blended yield
36.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

JAMF
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$13.02
-0.2% upside vs current
Range: $13.00 — $13.05
Altman Z
0.6
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JAMF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJAMFPFE
Forward yield15.33%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$22.4K$49.6K
Annual income after 10y$1.71$26,258.71
Total dividends collected$1.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold
Analyst price target$13.02$27.50

Year-by-year: JAMF vs PFE ($10,000, DRIP)

YearJAMF PortfolioJAMF Income/yrPFE PortfolioPFE Income/yrGap
1$11,466$766.28$9,153$693.39+$2.3KJAMF
2$12,680$410.58$8,593$849.25+$4.1KJAMF
3$13,779$212.16$8,336$1,066.78+$5.4KJAMF
4$14,852$107.74$8,437$1,384.80+$6.4KJAMF
5$15,945$54.26$9,013$1,875.40+$6.9KJAMF
6$17,089$27.22$10,306$2,680.72+$6.8KJAMF
7$18,299$13.63$12,820$4,101.38+$5.5KJAMF
8$19,586$6.82$17,673$6,826.70+$1.9KJAMF
9← crossover$20,961$3.41$27,543$12,591.86$6.6KPFE
10$22,430$1.71$49,560$26,258.71$27.1KPFE

JAMF vs PFE: Complete Analysis 2026

JAMFStock

Jamf Holding Corp. offers a cloud software platform for Apple infrastructure and security platform worldwide. Its products include Jamf Pro, an Apple ecosystem management software solution for IT environments; Jamf Now, a pay-as-you-go Apple device management software solution for small-to-medium-sized businesses; Jamf School, a software solution for educators; Jamf Data Policy, a solution to enforce acceptable usage policies to eliminate shadow IT and block risky content and manage data consumption with real-time analytics and granular reporting; and Jamf Connect that streamlines Mac authentication and identity management; and Jamf Private Access, a ZTNA solution that replaces legacy conditional access and VPN technology. The company also offers Jamf Protect, which provides protection of Mac-targeted malware and creates customized telemetry and detections that give enterprise security teams visibility into their Macs; Jamf Threat Defense, a solution to protect workers from malicious attackers; and Jamf Nation, an online community of IT and security professionals focusing on Apple in the enterprise. It sells its SaaS solutions through a subscription model, direct sales force, and online, as well as indirectly through channel partners, including Apple. The company was founded in 2002 and is headquartered in Minneapolis, Minnesota.

Full JAMF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this JAMF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JAMF vs SCHDJAMF vs JEPIJAMF vs OJAMF vs KOJAMF vs MAINJAMF vs JNJJAMF vs MRKJAMF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.